Abstract |
Three patients with Hypokalemic Periodic Paralysis (HOPP)-associated progressive interattack muscle weakness, who became unresponsive or worsened by acetazolamide, responded favorably to dichlorophenamide, a more potent carbonic anhydrase inhibitor. Dichlorophenamide in single-blind placebo-controlled trials, considerably improved functional strength in two of the patients and had a moderate but definite effect in the third. Muscle groups graded 4/5 (MRC scale)returned to normal; very weak (0-3/5) atrophic muscles, improved to a minor degree. In one patient with acetazolamide-resistant paralytic attacks, dichlorophenamide also diminished the frequency and severity of the acute attacks. Dichlorophenamide had, in the present study, less effect than acetazolamide in reducing serum HCO3(-) and elevating Cl-. Its effectiveness may be related to the degree of sensitivity of certain HOPP patients to alterations of Cl- and/or HCO3(-) serum levels or to a different action of the drug unrelated to carbonic anhydrase inhibition or acidosis. Dichlorophenamide should be considered as an alternate to acetazolamide in the treatment of patients with HOPP-associated interattack muscle weakness who have become unresponsive or worsened by acetazolamide.
|
Authors | M C Dalakas, W K Engel |
Journal | Muscle & nerve
(Muscle Nerve)
1983 Mar-Apr
Vol. 6
Issue 3
Pg. 182-6
ISSN: 0148-639X [Print] United States |
PMID | 6855804
(Publication Type: Case Reports, Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Dichlorphenamide
(pharmacology, therapeutic use)
- Humans
- Hypokalemia
(complications, drug therapy)
- Male
- Middle Aged
- Muscles
(drug effects)
- Muscular Atrophy
(drug therapy, pathology)
- Paralyses, Familial Periodic
(drug therapy, etiology, pathology)
|